Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: JOEBT1 who wrote (18948)	4/12/1998 12:48:00 PM
From: squetch	Read Replies (1) \| Respond to of 32384

I found this paper from Wyeth-Ayerst. TNF-alpha and 9-cis-RA Synergistically Induce ICAM-1 Expression: Evidence for Interaction of Retinoid Receptors w/ NF-kB >>This study provides the first demonstration fo a synergistic control of ICAM-1 protein expression by TNF-alpha and 9-cis-RA...In summary, this study demonstrates that ICAM-1 is synergistically regulated at the transcriptional level by TNF-a and 9-cis, via the functional interaction of NF-kB p65 homodimers w/ RAR/RXR heterodimers. Since enhanced ICAM-1 expression occurs in a number of diseases and pathological conditions, including atherosclerosis, arthritis, nephritis, and stroke, it is possibe that retinoid receptor/NF-kB(Nuclear factor kappa B) interaction may play a role in the progression of such disaeses.<< Experimental Cell Research 239, 423-429 Chadwick, Shaw and Winneker

To: JOEBT1 who wrote (18948)	4/12/1998 4:13:00 PM
From: Henry Niman	Respond to of 32384

Here's what H&Q had to say about the sector: April 09, 1998 Synopsis The Case for Biotech: A Rally Approaches The biotechnology sector has underperformed the market overall for several years. While several new sector stars have emerged during this period, the group as a whole has lagged compared to indices representing small cap, technology, or healthcare stocks, such as NASDAQ, SOX, or DRG. The reasons for this relative weakness include the following: The market's surge has been dominated by large cap companies. Technology stocks have attracted the majority of speculative, small cap investor interest. Biotech product failures continue to routinely cut market caps in half or worse, confirming investor fears of the risks involved in investing in the sector. Q1 Earnings Preview for Biotechnology Companies